Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Summit Therapeu ADR
(NQ:
SMMT
)
4.360
-0.030 (-0.68%)
Streaming Delayed Price
Updated: 1:39 PM EDT, May 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Summit Therapeu ADR
< Previous
1
2
Next >
Summit Therapeutics’ Rights Offering Nearing Expiration Date
February 23, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million
January 30, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
January 20, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
June 09, 2022
Via
AB Newswire
Exposures
Product Safety
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
June 06, 2022
Via
AB Newswire
Exposures
Product Safety
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
March 28, 2022
Via
AB Newswire
Exposures
Product Safety
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
March 07, 2022
Via
AB Newswire
Acurx Pharmaceuticals’ Ibezapolstat Takes Center Stage After Summit Therapeutics Misses Phase 3 C.Diff Trial Endpoints (NASDAQ: ACXP)
January 03, 2022
Via
AB Newswire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm
December 28, 2021
From
The Schall Law Firm
Via
Business Wire
AcurX Pharmaceuticals’ C. Difficile Drug Candidate Could Fetch $800 Million On A Peer Comparison Basis (NASDAQ: ACXP)
October 20, 2021
Via
AB Newswire
Exposures
Product Safety
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.